Attached files
file | filename |
---|---|
S-1/A - AMENDMENT NO. 1 TO FORM S-1 - KEMPHARM, INC | d793437ds1a.htm |
EX-1.1 - EX-1.1 - KEMPHARM, INC | d793437dex11.htm |
EX-2.1 - EX-2.1 - KEMPHARM, INC | d793437dex21.htm |
EX-3.2 - EX-3.2 - KEMPHARM, INC | d793437dex32.htm |
EX-10.1 - EX-10.1 - KEMPHARM, INC | d793437dex101.htm |
EX-10.11 - EX-10.11 - KEMPHARM, INC | d793437dex1011.htm |
EX-10.14 - EX-10.14 - KEMPHARM, INC | d793437dex1014.htm |
EX-10.10 - EX-10.10 - KEMPHARM, INC | d793437dex1010.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the reference to our firm under the caption Experts and to the use of our report dated March 11, 2015, except for the effect of the reverse stock split discussed in the fifth paragraph of Note 16 to the financial statements, as to which the date is April 3, 2015, in Amendment No. 1 to the Registration Statement (Form S-1 No. 333-202660) and related Prospectus of KemPharm, Inc. for the registration of shares of its common stock.
/s/ Ernst & Young LLP
Minneapolis, Minnesota
April 3, 2015